18:25 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

Antibodies neutralize Catalyst's Factor IX variant

Catalyst Biosciences Inc. (NASDAQ:CBIO) reported that two patients developed neutralizing antibodies to its CB 2679d (ISU 304). The antibodies were observed after treatment in the sixth and latest dose cohort of a Phase I/II trial...
23:12 , Jun 18, 2018 |  BC Extra  |  Clinical News

Antibodies neutralize Catalyst's Factor IX variant, crater stock

Catalyst Biosciences Inc. (NASDAQ:CBIO) fell $16.14 (64%) to $9.11 Monday when it reported that two patients developed neutralizing antibodies to CB 2679d (ISU 304). The antibodies were observed after treatment in the sixth and latest...
02:15 , Dec 16, 2017 |  BioCentury  |  Product Development

Assessing the BCMA scene

Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric antigen receptor therapy the leader of the pack of CARs that presented clinical...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Company News

Catalyst Biosciences hematology news

Catalyst will reduce headcount by 10 (50%) to about 10 to focus resources on its hemostasis programs, primarily CB 813d and CB 2679d ( ISU 304). The company said it will continue to...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Company News

Catalyst Biosciences, Targacept deal

Targacept and Catalyst will merge, with Catalyst shareholders owning about 65% of the combined company and Targacept shareholders owning the remaining portion. The resulting company expects to have $40 million at closing. Targacept will provide...
07:00 , Oct 14, 2013 |  BC Week In Review  |  Company News

Catalyst Biosciences, Isu Abxis deal

Catalyst and Isu partnered to develop Catalyst's FIX-NG ( CB 2679d) through Phase I testing to prevent and treat bleeding in hemophilia B patients. The recombinant Factor IX protein is in preclinical testing,...
07:00 , Oct 14, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones BioDelivery Sciences International Inc. (NASDAQ:BDSI) was down $0.45 to $5.15 last week after FDA accepted for review an NDA for Bunavail buprenorphine naloxone to treat opioid dependence. The company expects a decision by early...
23:42 , Oct 9, 2013 |  BC Extra  |  Company News

Catalyst, Isu Abxis partner for Catalyst's Factor IX

Catalyst Biosciences Inc. (South San Francisco, Calif.) and Isu Abxis Co. Ltd. (KOSDAQ:086890) partnered to develop Catalyst's FIX-NG (CB 2679d) through Phase I testing to prevent and treat bleeding in hemophilia B patients. The recombinant...